HDL Dysfunction During the Acute Stage of Stroke
- Conditions
- Stroke, Acute
- Registration Number
- NCT03245957
- Lead Sponsor
- Centre Hospitalier Universitaire de la Réunion
- Brief Summary
The study investigates the effect of plasma myeloperoxidase (MPO) concentrations on HDL dysfunction during the acute stage of ischemic and haemorrhagic strokes.
- Detailed Description
MRI or CT scan are used to confirm the diagnosis of haemorrhagic, ischemic and mimick stroke.
Plasma anf HDL-MPO concentrations, as well as potent HDL dysfunction, are compared in the 3 cases.
The investigators hypothesis is that MPO concentrations and subsequent HDL dysfunction could be higher in ischemic strokes than in haemorrhagic ones. MPO could be a examined as a potent marker of early stage of ischemic stroke.
Plasma MPO levels could also be discriminant regarding the mimick strokes in patient exhibiting stroke clinical picture.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 112
Patients with less than 12 hours stroke clinical signs:
- hemiparesis or hemiplegia
- unilateral sensitivity disorder
- language impairment
- balance disorder
- dizziness, bilateral or monocular vision totally or partially lost
- Pregnancy
- head trauma since the last 3 months
- stroke since the last 3 months
- myocardial infarction since the last 3 months
- patient disagrees to be enrolled in the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma MPO concentrations Through study completion, an average of 6 hours Assessment of plasma MPO concentrations during acute stage of stroke
- Secondary Outcome Measures
Name Time Method HDL-MPO concentrations Through study completion, an average of 6 hours Assessment of HDL-MPO concentrations during acute stage of stroke
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Chu Reunion Island
🇷🇪Saint-Pierre, Reunion Island, Réunion
Chu Reunion Island🇷🇪Saint-Pierre, Reunion Island, RéunionCOURET DAVID, MDContact+262262359000david.couret@chu-reunion.fr